利用工程化的三聚体刺突蛋白受体结合域抑制细胞系统中的 SARS-CoV-2 感染。

Inhibition of SARS-CoV-2 infection in cellular systems using engineered trimeric receptor-binding domain of spike protein.

机构信息

Department of Pathology, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA.

Department of Pathology, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA; The Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA; Department of Biochemistry, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA.

出版信息

STAR Protoc. 2023 Mar 17;4(1):102127. doi: 10.1016/j.xpro.2023.102127. Epub 2023 Feb 10.

DOI:10.1016/j.xpro.2023.102127

PMID:36853707

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9915046/

Abstract

Here, we provide a protocol for the design, expression, purification, and functional studies of an engineered trimeric version of the receptor-binding domain (tRBD) of SARS-CoV-2 spike protein. We describe the use of tRBD to block SARS-CoV-2 spike pseudovirus and true virus binding to cellular angiotensin converting enzyme-2 (ACE2), thereby blocking viral infection. This protocol is applicable to generate a trimeric version of any protein of interest. For complete details on the use and execution of this protocol, please refer to Basavarajappa et al. (2022)..

摘要

在这里，我们提供了一种设计、表达、纯化和功能研究 SARS-CoV-2 刺突蛋白受体结合域（tRBD）工程化三聚体的方案。我们描述了使用 tRBD 阻断 SARS-CoV-2 刺突假病毒和真病毒与细胞血管紧张素转换酶-2（ACE2）的结合，从而阻断病毒感染。该方案适用于生成任何感兴趣的蛋白质的三聚体版本。有关此方案的使用和执行的完整详细信息，请参阅 Basavarajappa 等人。（2022 年）。